Prometheus Biosciences Valuation

Prometheus Biosciences Investor Information

About 17.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 3.54. Prometheus Biosciences had not issued any dividends in recent years. The entity had 1:100 split on the 1st of November 2013. Based on the key indicators related to Prometheus Biosciences' liquidity, profitability, solvency, and operating efficiency, Prometheus Biosciences is not in a good financial situation at the moment. It has a very high risk of going through financial straits in January.

Prometheus Biosciences Asset Utilization

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Prometheus Biosciences has an asset utilization ratio of 0.92 percent. This suggests that the Company is making $0.009192 for each dollar of assets. An increasing asset utilization means that Prometheus Biosciences is more efficient with each dollar of assets it utilizes for everyday operations.

Prometheus Biosciences Ownership Allocation

Prometheus Biosciences owns a total of 47.81 Million outstanding shares. The majority of Prometheus Biosciences outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Prometheus Biosciences to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Prometheus Biosciences. Please pay attention to any change in the institutional holdings of Prometheus Biosciences as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.

Prometheus Biosciences Profitability Analysis

The company reported the previous year's revenue of 6.81 M. Net Loss for the year was (141.75 M) with loss before overhead, payroll, taxes, and interest of (106.04 M).

Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.

Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.

If you are still planning to invest in Prometheus Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Prometheus Biosciences' history and understand the potential risks before investing.